Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

  • Yuto Unoh
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Shota Uehara
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Kenji Nakahara
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Haruaki Nobori
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Yukiko Yamatsu
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Shiho Yamamoto
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Yuki Maruyama
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Yoshiyuki Taoda
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Koji Kasamatsu
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Takahiro Suto
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Kensuke Kouki
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Atsufumi Nakahashi
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Sho Kawashima
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Takao Sanaki
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Shinsuke Toba
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Kentaro Uemura
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Tohru Mizutare
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Shigeru Ando
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Michihito Sasaki
    International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan
  • Yasuko Orba
    International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan
  • Hirofumi Sawa
    International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan
  • Akihiko Sato
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Takafumi Sato
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Teruhisa Kato
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan
  • Yuki Tachibana
    Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan

書誌事項

公開日
2022-03-30
権利情報
  • https://creativecommons.org/licenses/by/4.0/
DOI
  • 10.1021/acs.jmedchem.2c00117
  • 10.1101/2022.01.26.477782
公開者
American Chemical Society (ACS)

この論文をさがす

説明

<jats:title>Abstract</jats:title><jats:p>The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths and threatens public health and safety. Despite the rapid global spread of COVID-19 vaccines, effective oral antiviral drugs are urgently needed. Here, we describe the discovery of S-217622, the first oral non-covalent, non-peptidic SARS-CoV-2 3CL protease inhibitor clinical candidate. S-217622 was discovered <jats:italic>via</jats:italic> virtual screening followed by biological screening of an in-house compound library, and optimization of the hit compound using a structure-based drug-design strategy. S-217622 exhibited antiviral activity <jats:italic>in vitro</jats:italic> against current outbreaking SARS-CoV-2 variants and showed favorable pharmacokinetic profiles <jats:italic>in vivo</jats:italic> for once-daily oral dosing. Furthermore, S-217622 dose-dependently inhibited intrapulmonary replication of SARS-CoV-2 in mice, indicating that this novel non-covalent inhibitor could be a potential oral agent for treating COVID-19.</jats:p>

収録刊行物

被引用文献 (42)*注記

もっと見る

関連研究データ

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ